Zenas BioPharma (NASDAQ:ZBIO) Shares Down 7.1% – What’s Next?

Zenas BioPharma, Inc. (NASDAQ:ZBIO) shares traded down 7.1% during mid-day trading on Thursday . The company traded as low as $20.80 and last traded at $20.95. 74,322 shares changed hands during mid-day trading, a decline of 96% from the average session volume of 1,899,418 shares. The stock had previously closed at $22.56.

Wall Street Analyst Weigh In

A number of analysts have commented on the stock. Jefferies Financial Group restated a “buy” rating and set a $48.00 price target on shares of Zenas BioPharma in a research note on Tuesday, January 6th. Weiss Ratings reissued a “sell (d-)” rating on shares of Zenas BioPharma in a research report on Monday, December 29th. Wedbush restated an “outperform” rating and issued a $45.00 target price on shares of Zenas BioPharma in a report on Monday, December 22nd. HC Wainwright reaffirmed a “buy” rating on shares of Zenas BioPharma in a research report on Tuesday, December 16th. Finally, Wall Street Zen downgraded Zenas BioPharma from a “hold” rating to a “sell” rating in a research note on Saturday, January 10th. Six investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $43.14.

Zenas BioPharma Stock Performance

The company’s 50 day moving average price is $34.38 and its 200-day moving average price is $24.35. The stock has a market cap of $1.09 billion, a P/E ratio of -2.88 and a beta of -1.45. The company has a debt-to-equity ratio of 0.37, a quick ratio of 5.66 and a current ratio of 5.66.

Zenas BioPharma (NASDAQ:ZBIO) last released its quarterly earnings results on Wednesday, November 12th. The company reported ($1.22) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.87) by ($0.35).

Insider Buying and Selling at Zenas BioPharma

In other Zenas BioPharma news, CEO Leon O. Moulder, Jr. bought 50,000 shares of Zenas BioPharma stock in a transaction dated Wednesday, January 7th. The stock was bought at an average cost of $16.38 per share, with a total value of $819,000.00. Following the completion of the acquisition, the chief executive officer directly owned 316,155 shares in the company, valued at approximately $5,178,618.90. The trade was a 18.79% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In the last quarter, insiders purchased 100,000 shares of company stock valued at $1,639,000. 16.50% of the stock is owned by insiders.

Institutional Trading of Zenas BioPharma

A number of hedge funds have recently bought and sold shares of ZBIO. Quarry LP grew its stake in Zenas BioPharma by 34.5% in the 3rd quarter. Quarry LP now owns 1,134 shares of the company’s stock valued at $25,000 after purchasing an additional 291 shares during the period. Russell Investments Group Ltd. purchased a new position in shares of Zenas BioPharma in the 3rd quarter worth about $30,000. BNP Paribas Financial Markets increased its holdings in Zenas BioPharma by 120.0% during the third quarter. BNP Paribas Financial Markets now owns 3,146 shares of the company’s stock worth $70,000 after buying an additional 1,716 shares during the last quarter. PNC Financial Services Group Inc. raised its position in Zenas BioPharma by 41.2% in the second quarter. PNC Financial Services Group Inc. now owns 9,179 shares of the company’s stock worth $89,000 after acquiring an additional 2,679 shares during the period. Finally, Creative Planning purchased a new position in Zenas BioPharma in the third quarter valued at about $264,000.

Zenas BioPharma Company Profile

Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.